The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for cerliponase alfa (BioMarin Pharmaceuticals Australia Pty Ltd)
Active ingredients
cerliponase alfa
Date of review outcome
Lapse date
Type
Priority review
Indication
For the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.
Registration date